351 related articles for article (PubMed ID: 19597003)
21. Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design.
Sadanand S; Suscovich TJ; Alter G
Annu Rev Med; 2016; 67():185-200. PubMed ID: 26565674
[TBL] [Abstract][Full Text] [Related]
22. Vaccine nanoparticles for protection against HIV infection.
Aikins ME; Bazzill J; Moon JJ
Nanomedicine (Lond); 2017 Mar; 12(6):673-682. PubMed ID: 28244816
[TBL] [Abstract][Full Text] [Related]
23. Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits.
Jiang X; Totrov M; Li W; Sampson JM; Williams C; Lu H; Wu X; Lu S; Wang S; Zolla-Pazner S; Kong XP
J Virol; 2016 Dec; 90(24):11007-11019. PubMed ID: 27707920
[TBL] [Abstract][Full Text] [Related]
24. A global approach to HIV-1 vaccine development.
Stephenson KE; Barouch DH
Immunol Rev; 2013 Jul; 254(1):295-304. PubMed ID: 23772627
[TBL] [Abstract][Full Text] [Related]
25. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
26. New concepts in HIV-1 vaccine development.
Stephenson KE; D'Couto HT; Barouch DH
Curr Opin Immunol; 2016 Aug; 41():39-46. PubMed ID: 27268856
[TBL] [Abstract][Full Text] [Related]
27. Vaccines and vaccine strategies against HIV.
Stratov I; DeRose R; Purcell DF; Kent SJ
Curr Drug Targets; 2004 Jan; 5(1):71-88. PubMed ID: 14738219
[TBL] [Abstract][Full Text] [Related]
28. New approaches to design HIV-1 T-cell vaccines.
Perrin H; Canderan G; Sékaly RP; Trautmann L
Curr Opin HIV AIDS; 2010 Sep; 5(5):368-76. PubMed ID: 20978376
[TBL] [Abstract][Full Text] [Related]
29. Architectural insight into inovirus-associated vectors (IAVs) and development of IAV-based vaccines inducing humoral and cellular responses: implications in HIV-1 vaccines.
Hassapis KA; Stylianou DC; Kostrikis LG
Viruses; 2014 Dec; 6(12):5047-76. PubMed ID: 25525909
[TBL] [Abstract][Full Text] [Related]
30. HIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells.
Wee EG; Ondondo B; Berglund P; Archer J; McMichael AJ; Baltimore D; Ter Meulen JH; Hanke T
Mol Ther; 2017 Feb; 25(2):494-503. PubMed ID: 28153096
[TBL] [Abstract][Full Text] [Related]
31. Current progress in the development of a prophylactic vaccine for HIV-1.
Gamble LJ; Matthews QL
Drug Des Devel Ther; 2010 Dec; 5():9-26. PubMed ID: 21267356
[TBL] [Abstract][Full Text] [Related]
32. Complex immune correlates of protection in HIV-1 vaccine efficacy trials.
Tomaras GD; Plotkin SA
Immunol Rev; 2017 Jan; 275(1):245-261. PubMed ID: 28133811
[TBL] [Abstract][Full Text] [Related]
33. Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design.
Srivastava IK; Ulmer JB; Barnett SW
Expert Rev Vaccines; 2004 Aug; 3(4 Suppl):S33-52. PubMed ID: 15285704
[TBL] [Abstract][Full Text] [Related]
34. The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors.
Koup RA; Graham BS; Douek DC
Nat Rev Immunol; 2011 Jan; 11(1):65-70. PubMed ID: 21164527
[TBL] [Abstract][Full Text] [Related]
35. AIDS vaccine test to be expanded based on upbeat results.
AIDS Read; 2005 Nov; 15(11):561, 573. PubMed ID: 16329176
[No Abstract] [Full Text] [Related]
36. Virus-like vaccines against HIV/SIV synergize with a subdominant antigen T cell vaccine.
Schwerdtfeger M; Andersson AC; Neukirch L; Holst PJ
J Transl Med; 2019 May; 17(1):175. PubMed ID: 31126293
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic HIV-1 vaccine: time for immunomodulation and combinatorial strategies.
Seddiki N; Lévy Y
Curr Opin HIV AIDS; 2018 Mar; 13(2):119-127. PubMed ID: 29329113
[TBL] [Abstract][Full Text] [Related]
38. HIV-1 vaccines and adaptive trial designs.
Corey L; Nabel GJ; Dieffenbach C; Gilbert P; Haynes BF; Johnston M; Kublin J; Lane HC; Pantaleo G; Picker LJ; Fauci AS
Sci Transl Med; 2011 Apr; 3(79):79ps13. PubMed ID: 21508308
[TBL] [Abstract][Full Text] [Related]
39. Immune Correlate-Guided HIV Vaccine Design.
Alter G; Barouch D
Cell Host Microbe; 2018 Jul; 24(1):25-33. PubMed ID: 30001521
[TBL] [Abstract][Full Text] [Related]
40. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).
Kibuuka H; Kimutai R; Maboko L; Sawe F; Schunk MS; Kroidl A; Shaffer D; Eller LA; Kibaya R; Eller MA; Schindler KB; Schuetz A; Millard M; Kroll J; Dally L; Hoelscher M; Bailer R; Cox JH; Marovich M; Birx DL; Graham BS; Michael NL; de Souza MS; Robb ML
J Infect Dis; 2010 Feb; 201(4):600-7. PubMed ID: 20078213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
